전이성 대장암에서 K-ras 돌연변이

Abstract

ABSTRACT

K-ras Gene Mutations in the metastatic ColoRectal Cancer

Kang, Ji-Eun Advisor : Prof. Park, Chi-young, M.D. Department of Medicine, Graduate School of Chosun University

Purpose: The anti-epidermal growth factor receptor cetuximab has been proven to be efficient in metastatic colorectal cacner(mCRC). This study was aimed to evaluate the prevalence and prognostic implication of k-ras mutation in 20 mCRC treated with/without cetuximab, in Korea.

Methods: Patients with mCRC treated with/without cetuximab with available archival tissue specimens were included. K-ras mutation was analyzed using polymerase chain reaction-single strand conformation polymorphism(PCR-SSCP) and several clinical variables, including response rate of chemotherapy were obtained.

Results: K-ras mutation was detected in 6 of 20 patients (30%). Response rates to cytotoxic chemotherapy were 42.9 % and 16.7 % for the wild and mutant k-ras(p value 0.277). Respone rate to cetuximab treatment among patients with wild type k-ras tumors was 20%.

Conclusion: In korea, prevalence of k-ras mutation in mCRC was similar, but response rate to cetuximab treatment among wild k-ras patients was relatively low.

Keywords : colorectal, k-ras, cetuximab